Inhaler pricing and accessibility
Pro Research Analysisby 
Searched over 200M research papers
Inhaler Pricing and Accessibility: Global and Regional Insights
Inhaler Availability in Low- and Middle-Income Countries
Access to essential inhalers for asthma and chronic obstructive pulmonary disease (COPD) is a significant challenge in many low- and middle-income countries (LMICs). Studies show that the availability of inhaled corticosteroids (ICS) and combination inhalers is particularly poor, with only a small fraction of countries meeting the World Health Organization's (WHO) target of 80% availability in health facilities. For example, only 6 out of 58 countries met this target for short-acting beta-agonists (SABAs), and just 3 out of 48 for ICS inhalers. Combination inhalers containing both ICS and long-acting beta-agonists (LABA) were even less available, with none of the surveyed countries reaching the target . This lack of availability is especially pronounced in public sector facilities, where low-income populations typically seek care 124.
Inhaler Pricing and Affordability
The cost of inhalers varies widely across countries and regions. In many LMICs, the price of inhalers is often several times higher than international reference prices (IRPs), and the affordability remains a major barrier. For instance, purchasing a single inhaler can cost between 1.6 and 7 days’ wages for the lowest-paid government worker, making these medicines unaffordable for the majority of the population 124. Even in countries where generic versions are available, high markups and inefficient procurement systems can keep prices elevated 24. In India, for example, the price of beclomethasone and salbutamol inhalers ranged from 0.74 to 1.49 times the IRP, but these costs still represented a significant portion of a low-income worker’s salary .
Impact of Health Policies and Subsidies
Some countries have implemented policies to improve inhaler accessibility, such as including inhalers in national reimbursement lists or negotiating lower prices through national drug price negotiations. In China, the inclusion of single-inhaler triple therapy medicines for COPD in the Medicare catalog led to a significant drop in prices and improved both availability and affordability. After these policies were enacted, the cost of a month’s supply of these inhalers dropped to about 1.3 days of minimum wage after reimbursement, and their availability in hospitals increased notably .
Barriers in High-Income Countries
Even in high-income countries, inhaler pricing and accessibility remain problematic. In the United States, inhaler prices are high due to limited generic competition and rising brand-name drug prices. Out-of-pocket costs can reach up to $700 per month for a single inhaler, making them unaffordable for many patients even with insurance 567. Manufacturer coupons and discount programs exist but are often complex, vary by insurance plan, and can be difficult for patients and providers to navigate . Additionally, insurance formularies and preferred drug lists can restrict access, leading to non-medical switching and administrative burdens for healthcare providers .
Trends in Inhaler Spending
In the U.S., Medicare Part D spending on inhalers has increased significantly, driven by both rising prices and high utilization rates among patients with asthma and COPD. The lack of generic alternatives and increasing brand-name prices have contributed to this trend, highlighting the need for policy interventions to control costs and improve access for seniors and other vulnerable populations .
Conclusion
Globally, the pricing and accessibility of inhalers for asthma and COPD remain major challenges, particularly in low- and middle-income countries but also in high-income settings. Poor availability in public health facilities, high prices relative to wages, and complex insurance and reimbursement systems all contribute to limited access. Policy measures such as national price negotiations, inclusion in reimbursement lists, and efforts to increase generic competition can help improve both affordability and availability, but significant gaps remain that require ongoing attention and action 1234+3 MORE.
Sources and full results
Most relevant research papers on this topic